Clinical Trials: Page 2

  • Data
    Image attribution tooltip

    AdobeStock/ Eakkachai

    Image attribution tooltip
    Sponsored by TriNetX

    Improving clinical trial design with real-world data

    Leveraging real-world data (RWD) transforms global clinical trials, enhancing patient engagement and improving regulatory decision-making.

    March 25, 2024
  • A Roche logo is seen on the side of a building.
    Image attribution tooltip
    Courtesy of Roche
    Image attribution tooltip

    Roche autoimmune disease drug disappoints in closely watched trial

    Though the medicine hit its goal in a Phase 3 study in myasthenia gravis, the results fell short of expectations in a boost to rival drug developers like Argenx and AstraZeneca.

    By • March 21, 2024
  • An injection pen containing the drug semaglutide lies on a white plate. Explore the Trendline➔
    Image attribution tooltip
    Douglas Cliff via Getty Images
    Image attribution tooltip
    Trendline

    The obesity drug revolution

    GLP-1 agonists like Ozempic and Wegovy can drive significant weight loss and, at least in Wegovy’s case, protect the heart. Their adoption is changing how doctors treat obesity. 

    By BioPharma Dive staff
  • A double exposure photo illustration of a glass flask and a scientist holding a tube in a laboratory, with stock market information in the background.
    Image attribution tooltip
    MadamLead via Getty Images
    Image attribution tooltip

    Acelyrin eye drug heads to late-stage testing after trial win

    The biotech, which raised $540 million in an initial public offering last year, is pitching the medicine as a potential challenger to Amgen’s blockbuster eye drug Tepezza.

    By • March 20, 2024
  • The logo of German pharmaceuticals and chemicals giant Bayer stands over Bayer corporate offices on September 14, 2016 in Berlin, Germany.
    Image attribution tooltip
    Sean Gallup via Getty Images
    Image attribution tooltip

    With new data, Bayer readies rival to Astellas menopause drug

    Following a third successful Phase 3 trial, the company is planning approval filings for the medicine, which it acquired in a $425 million deal four years ago.

    By • March 19, 2024
  • Merck sign
    Image attribution tooltip
    Marko Georgiev / Stringer via Getty Images
    Image attribution tooltip

    Merck reveals plans to develop newer HPV shots

    The pharma intends to test a single-dose regimen as well as a shot that may provide broader protection than the current versions of Gardasil that regularly generate billions in annual sales.

    By • March 13, 2024
  • An illustration of neuron cells in abstract dark space.
    Image attribution tooltip
    whitehoune via Getty Images
    Image attribution tooltip

    Acadia drug fails schizophrenia trial, setting back company’s expansion plans

    The setback shuts out Acadia’s top medicine from a large sales opportunity and heightens the biotech’s dependence on a pipeline filled with risky drug prospects. 

    By Kristin Jensen • March 12, 2024
  • A scientific illustration of amyloid plaques and neurons, colored in blue and orange.
    Image attribution tooltip
    selvanegra via Getty Images
    Image attribution tooltip

    Roche, following setbacks, turns to its next Alzheimer’s drug

    Roche said its experimental Alzheimer’s disease drug trontinemab showed it might be able to clear brain plaques faster than other medicines.

    By • March 11, 2024
  • A photograph of Amylyx Pharmaceuticals cofounders Josh Cohen and Justin Klee.
    Image attribution tooltip
    Permission granted by Amylyx Pharmaceuticals
    Image attribution tooltip
    Q&A

    Amylyx CEOs look for a path forward following major setback

    Justin Klee and Joshua Cohen spoke to BioPharma Dive about the next steps for their company, which is considering pulling its only product from market after the drug failed a confirmatory study in ALS.

    By • March 11, 2024
  • The logo of Amylyx Pharmaceuticals is seen through an office window.
    Image attribution tooltip
    Permission granted by Amylyx Pharmaceuticals
    Image attribution tooltip

    Amylyx ALS drug fails crucial study, putting company’s future in doubt

    The results have led Amylyx to pause promotion of Relyvrio and potentially pull it from the market in the coming weeks, a major blow to the company and ALS patients.

    By • Updated March 8, 2024
  • A conceptual illustration of neural activity in a brain.
    Image attribution tooltip
    nopparit via Getty Images
    Image attribution tooltip

    NodThera says inflammation drug has positive effect in Parkinson’s

    The results from the privately held biotech add to early evidence supporting the potential of an increasingly popular drug target known as NLRP3 inflammasomes.

    By • March 7, 2024
  • White flags bearing Novo Nordisk's logo are seen against a blue sky.
    Image attribution tooltip
    Courtesy of Novo Nordisk
    Image attribution tooltip

    Novo’s latest obesity pill spurs major weight loss in small trial

    Early results from a Phase 1 study suggest the drug, amycretin, could be as potent as injectable medicines already sold by Novo and rival Eli Lilly.

    By • March 7, 2024
  • Image attribution tooltip
    Alnylam Pharmaceuticals, Inc.
    Image attribution tooltip

    Alnylam, Roche blood pressure drug scores in second mid-stage trial

    The study results further validate Roche’s recent decision to acquire rights to the drug, which is being developed for people with a stubborn form of hypertension.

    By • March 5, 2024
  • A smiling man in a collared shirt poses for a photo
    Image attribution tooltip
    Courtesy of Apogee Therapeutics
    Image attribution tooltip

    Apogee data hint at potential for long-lasting eczema drug

    The biotech, which raised $300 million in an IPO last year, disclosed early results suggesting its therapy could be dosed less frequently than medicines from Eli Lilly and Regeneron. 

    By Kristin Jensen • March 5, 2024
  • An image of liver cirrhosis
    Image attribution tooltip
    klickit24 via Getty Images
    Image attribution tooltip

    Akero strengthens MASH drug’s case with new study data

    The updated results show that responses to the drug, which is currently in late-stage testing, deepened with time, helping the company rebound from an earlier setback.

    By • March 4, 2024
  • Illustration of doctor and patient discussing scientific biomedical shapes.
    Image attribution tooltip
    Permission granted by QIAGEN
    Image attribution tooltip
    Sponsored by QIAGEN

    Using knowledge graphs to drive drug discovery

    How are knowledge graphs changing the path of drug discovery?

    March 4, 2024
  • A conceptual illustration of neural activity in a brain.
    Image attribution tooltip
    nopparit via Getty Images
    Image attribution tooltip

    Incannex says psilocybin therapy lowered anxiety in small study

    Shares of the Australian biotech rocketed up about 55% after the company announced results from a mid-stage study in generalized anxiety disorder. 

    By • Feb. 28, 2024
  • Image attribution tooltip
    Elizabeth Regan / Industry Dive
    Image attribution tooltip

    Viking data suggest obesity drug could rival Zepbound, Wegovy

    The biotech’s drug led to significant weight loss in a Phase 2 trial, causing shares to double as analysts compared results to the marks set by drugs from Eli Lilly and Novo Nordisk.

    By • Feb. 27, 2024
  • A concept illustration of malignant cells, colored purple and red
    Image attribution tooltip
    koto_feja via Getty Images
    Image attribution tooltip

    Janux shares triple on early cancer immunotherapy data

    Analysts viewed results for one of Janux’s drug, a T cell engager aimed at metastatic prostate cancer, as potentially best-in-class in a field that’s crowded with competitors.

    By • Feb. 27, 2024
  • Exterior of FDA headquarters
    Image attribution tooltip
    Courtesy of U.S. Food and Drug Administration
    Image attribution tooltip

    Minerva schizophrenia drug rejected by FDA

    The agency’s complete response letter knocks back Minerva’s attempt to secure approval of the drug over agency reviewers’ objections.

    By • Feb. 27, 2024
  • Image attribution tooltip
    Warren Little via Getty Images
    Image attribution tooltip

    GSK drug meets goal in late-stage gonorrhea study

    The drug, one of several GSK is developing for drug-resistant bacteria, has now succeeded in testing against two different infections.

    By • Feb. 26, 2024
  • A micrograph showing triglyceride fat accumulated inside liver cells.
    Image attribution tooltip
    Dr_Microbe via Getty Images
    Image attribution tooltip
    Obesity drugs

    Obesity drug from Boehringer, Zealand succeeds in MASH trial

    Zealand shares rose by more than one-third on the data, which provide further evidence so-called incretin drugs could help treat people with the liver disease.

    By • Feb. 26, 2024
  • An illustration of B cells producing antibodies
    Image attribution tooltip
    Love Employee via Getty Images
    Image attribution tooltip

    NEJM paper fills in details on ‘remarkable’ CAR-T result in autoimmune disease

    The full results spotlight cell therapy’s potential to treat lupus and other inflammatory conditions, but also the problems drugmakers must still solve.

    By • Feb. 21, 2024
  • An illustration of immune cells attacking a tumor.
    Image attribution tooltip
    Meletios Verras via Getty Images
    Image attribution tooltip

    Bavarian Nordic terminates cancer vaccine work

    The Danish company scrapped a vaccine in Phase 1 testing and will exit oncology altogether, focusing instead on infectious disease research.

    By • Feb. 21, 2024
  • A general view of AstraZeneca is seen during Prime Minister Scott Morrison's visit on August 19, 2020 in Sydney, Australia.
    Image attribution tooltip
    Lisa Maree Williams via Getty Images
    Image attribution tooltip

    AstraZeneca gets new Tagrisso OK as drug succeeds in another trial

    The FDA approved the targeted therapy together with chemo for first-line metastatic lung cancer, while fresh trial results supported earlier use.

    By • Feb. 20, 2024
  • Science technology concept. Research and Development. Drug discovery.
    Image attribution tooltip

    iStock / metamorworks

    Image attribution tooltip
    Sponsored by Allucent

    Translating complex data into actionable insights, to create big value for smaller biotech companies

    Why clinical pharmacology is critical to accelerating drug development, and how it can help drive value in a complex and rapidly evolving landscape.

    Feb. 20, 2024